C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 310—New DrugsSubpart C—New Drugs Exempted From Prescription-Dispensing Requirements

21 C.F.R. § 310.200 (2026)

Prescription-exemption procedure

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1977–2013 9citing cases
At a glance

Courts have cited this section in 9 opinions since 1977.

(a) Duration of prescription requirement. Any drug limited to prescription use under section 503(b)(1)(B) of the act remains so limited until it is exempted as provided in paragraph (b) or (e) of this section.

(b) Prescription-exemption procedure for drugs limited by a new drug application. Any drug limited to prescription use under section 503(b)(1)(B) of the act shall be exempted from prescription-dispensing requirements when the Commissioner finds such requirements are not necessary for the protection of the public health by reason of the drug's toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, and he finds that the drug is safe and effective for use in self-medication as directed in proposed labeling. A proposal to exempt a drug from the prescription-dispensing requirements of section 503(b)(1)(B) of the act may be initiated by the Commissioner or by any interested person. Any interested person may file a petition seeking such exemption, which petition may be pursuant to part 10 of this chapter, or in the form of a supplement to an approved new drug application.

(c) New drug status of drugs exempted from the prescription requirement. A drug exempted from the prescription requirement under the provisions of paragraph (b) of this section is a “new drug” within the meaning of section 201(p) of the act until it has been used to a material extent and for a material time under such conditions except as provided in paragraph (e) of this section.

(d) Prescription legend not allowed on exempted drugs. The use of the prescription caution statement quoted in section 503(b) (4) of the act, in the labeling of a drug exempted under the provisions of this section, constitutes misbranding. Any other statement or suggestion in the labeling of a drug exempted under this section, that such drug is limited to prescription use, may constitute misbranding.

(e) Prescription-exemption procedure of OTC drug review. A drug limited to prescription use under section 503(b)(1)(B) of the act may also be exempted from prescription-dispensing requirements by the procedure set forth in § 330.13 of this chapter.

[39 FR 11680, Mar. 29, 1974, as amended at 41 FR 32582, Aug. 4, 1976; 42 FR 4714, Jan. 25, 1977; 42 FR 15674, Mar. 22, 1977; 72 FR 15043, Mar. 30, 2007]
The 9 cases that cite 21 C.F.R. § 310.200 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENTummino v. Torti, 603 F. Supp. 2d 519 (E.D.N.Y. 2009).
cites § 310.200 2×cited by 15 cases
Where it cites § 310.200
“21 C.F.R. § 310.200 (b). Many new drugs are initially approved for prescription-only status and then later considered for nonprescription status, i.”
The case’s holding
An agency decision is arbitrary and capricious under the Administrative Procedure Act if it results from political interference, bad faith, or departures from normal procedures without reasoned explanation.
Later courts cite it for
“trusted to conduct a fair assessment of the scientific evidence.” · 2 citing courts
2
GREENTummino v. Von Eschenbach ex rel. Food & Drug Admin., 427 F. Supp. 2d 212 (E.D.N.Y. 2006).
cites § 310.200 2×cited by 15 cases
Where it cites § 310.200
“Under 21 C.F.R. § 310.200 (b), "[a] proposal to exempt a drug from the prescription-dispensing requirements of section 503(b)(1)(C) of the act may be initiated by the Commissioner or by any interested person.”
Later courts cite it for
“a delay that is the result of bad faith-that is, a delay for improper reasons-is a delay that is per se unreasonable. . . .” · 3 citing courts
3
GREENRobinson v. McNeil Consum. Healthcare, 615 F.3d 861 (7th Cir. 2010).
cites § 310.200 1×cited by 60 cases
Where it cites § 310.200
“The agency bases its decision on whether the drug is safe and effective for use without a doctor’s permission, 21 C.F.R. § 310.200 (b); and it has decided not to require that drugs containing ibuprofen be sold by prescription only.”
The case’s holding
An attorney's statement qualifies as a judicial admission only if it is deliberate, clear, and unambiguous.
Later courts cite it for
“a judicial admission is a statement, normally in a pleading, that negates a factual claim that the party making the statement might have made or considered making.” · 12 citing courts
4
GREENTummino v. Hamburg, 936 F. Supp. 2d 162 (E.D.N.Y. 2013).
cites § 310.200 2×cited by 7 cases
Where it cites § 310.200
“Indeed, 21 C.F.R. § 310.200 (b) expressly provides that the Commissioner may initiate, sua sponte, a proposal to exempt a drug from *175 prescription-dispensing requirements “when the Commissioner finds such requirements are not necessary for the protection of the public health.”
5
GREENAss'n of Am. Physicians & Surgeons v. Food & Drug Admin., 539 F. Supp. 2d 4 (D.D.C. 2008).
cites § 310.200 1×cited by 22 cases
Summary
No passage or summary on file for this case yet.
6
GREENParke, Davis & Co. v. Joseph A. Califano, 623 F.2d 1 (6th Cir. 1980).
cites § 310.200 1×cited by 39 cases
Where it cites § 310.200
“*4 Most of the documents which the district court ordered disclosed were generated in Parke Davis’s efforts to obtain OTC approval of Benylin under the “traditional” or “switch over” procedure prescribed in 21 C.F.R. § 310.200 . Section 310.200(b) provides, “[a]ny interested…”
The case’s holding
An agency invoking the FOIA deliberative process privilege must show how each withheld document fits into the decision-making process, rather than relying on conclusory affidavits of exemption.
Later courts cite it for
“the district court must know how each document fits into the deliberative process, and whether it is an essential element of that process or possibly a peripheral item which just 'beefs up' a position with cumulative materials.” · 3 citing courts
7
GREENTummino v. Hamburg, 260 F.R.D. 27 (E.D.N.Y. 2009).
cites § 310.200 2×cited by 5 cases
Summary
No passage or summary on file for this case yet.
8
GREENParke, Davis & Co. v. Califano, 564 F.2d 1200 (6th Cir. 1977).
cites § 310.200 2×cited by 17 cases
Where it cites § 310.200
“On November 25,1974 Parke Davis submitted a supplemental NDA seeking approval for *1202 over-the-counter marketing of Benylin under the traditional procedure prescribed in 21 CFR § 310.200 , known as a “switch over.”
9
GREENKaren Robinson v. McNeil Consum. Healthcare, No. 09-4011 (7th Cir. Aug. 11, 2010).
cites § 310.200 1×cited by 0 cases
Where it cites § 310.200
“The agency bases its decision on whether the drug is safe and effective for use without a doctor’s permission, 21 C.F.R. § 310.200 (b); and it has decided not to require that drugs containing ibuprofen be sold by prescription only.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197719952013

One bar per year. Tallest: 2 cases in 2009. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
E.D.N.Y46th Cir.27th Cir.2D.D.C.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com